Loading...
XNAS
SNOA
Market cap5mUSD
Jul 09, Last price  
3.20USD
1D
2.89%
1Q
53.85%
Jan 2017
-99.65%
IPO
-99.99%
Name

Sonoma Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
0.41
EPS
Div Yield, %
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
-7.66%
Revenues
13m
-4.05%
1,356,0002,584,0004,543,0003,835,0005,388,0007,364,0009,754,00012,744,00015,452,00013,668,00013,854,00015,084,00012,825,00016,658,00018,970,00018,936,00018,629,00012,628,00013,272,00012,735,000
Net income
-5m
L-6.13%
-16,530,000-23,099,000-19,783,000-20,339,000-17,656,000-8,232,000-7,948,000-7,329,000-5,431,0003,735,000-8,203,000-10,162,0009,274,000-14,328,000-11,798,000-2,946,000-4,615,000-5,086,000-5,151,000-4,835,000
CFO
-2m
L-61.02%
-13,533,000-20,520,000-18,082,000-17,446,000-16,832,000-6,639,000-4,429,000-4,032,0001,150,000-4,890,000-6,694,000-8,746,000-8,167,000-12,439,000-11,717,000-4,591,000-3,378,000-4,248,000-6,152,000-2,398,000
Earnings
Aug 06, 2025

Profile

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
IPO date
Jan 26, 2007
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
12,735
-4.05%
13,272
5.10%
Cost of revenue
17,436
17,842
Unusual Expense (Income)
NOPBT
(4,701)
(4,570)
NOPBT Margin
Operating Taxes
(196)
(33)
Tax Rate
NOPAT
(4,505)
(4,537)
Net income
(4,835)
-6.13%
(5,151)
1.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,784
2,868
BB yield
-59.01%
-86.55%
Debt
Debt current
521
943
Long-term debt
372
580
Deferred revenue
87
140
Other long-term liabilities
4,710
4,235
Net debt
(2,235)
(2,297)
Cash flow
Cash from operating activities
(2,398)
(6,152)
CAPEX
(17)
(269)
Cash from investing activities
(2)
(258)
Cash from financing activities
1,676
2,489
FCF
(3,848)
(11,730)
Balance
Cash
3,128
3,820
Long term investments
Excess cash
2,491
3,156
Stockholders' equity
(197,070)
(192,927)
Invested Capital
208,612
206,206
ROIC
ROCE
EV
Common stock shares outstanding
909
170
Price
3.33
-82.97%
19.53
-75.65%
Market cap
3,023
-8.76%
3,314
-98.44%
EV
788
1,017
EBITDA
(4,525)
(4,445)
EV/EBITDA
Interest
16
Interest/NOPBT